Osteoporosis News and Research

Latest Osteoporosis News and Research

Annual Society for Endocrinology BES conference to take place in UK from 11-14 April 2011

The annual Society for Endocrinology BES conference is taking place in Birmingham, UK from 11-14 April 2011.

18 Jan 2011

Research finds resistance training results in 20% decrease in person's blood pressure

Research conducted in the College of Health Sciences' Department of Health, Leisure and Exercise Science at Appalachian State University has shown that resistance training has some similar effects as aerobic exercise in lowering a person's blood pressure.

18 Jan 2011

Study: Pre-menopausal Chinese-American women have greater bone strength than Caucasian counterparts

A team of researchers at Columbia Engineering and Columbia University Medical Center announced today the results of the first study comparing bone structure in Chinese-American women to Caucasian women.

18 Jan 2011

USPSTF recommends women of ages 65 and above to routinely screen for osteoporosis

In an update to its 2002 recommendation, the U.S. Preventive Services Task Force now recommends that all women ages 65 and older be routinely screened for osteoporosis.

18 Jan 2011

Unintended direct conflict between pharmaceutical marketing and public health

Drugs that pharmaceutical companies market most aggressively to physicians and patients tend to offer less benefit and more harm to most patients - a phenomenon described as the "inverse benefit law" in a paper from the University of Texas Medical Branch at Galveston.

14 Jan 2011

Patients' and doctors' perceptions of osteoporosis management differ

Newly released findings of a multinational survey conducted on behalf of the International Osteoporosis Foundation (IOF) show clear disparities between patients' and doctors' perceptions of osteoporosis and its management.

12 Jan 2011

IOF welcomes EU Council Conclusions on chronic diseases, urges action in member states

According to the World Health Organization, chronic diseases are by far the leading cause of mortality in the world, representing 60% of all deaths worldwide and imposing an enormous burden on patients, their families and on society as a whole.

12 Jan 2011

TransPharma reports positive results from ViaDerm-Calcitonin Phase 1 trial for musculoskeletal disorders

TransPharma Medical Ltd., a specialty pharmaceutical company focused on the development and commercialization of drug products utilizing a proprietary active transdermal drug delivery technology, announced today successful results of a Phase I clinical trial of its self-applied ViaDerm-Calcitonin product for the treatment of musculoskeletal disorders such as osteoarthritis and musculoskeletal pain.

11 Jan 2011

New guidelines for accurate diagnosis, effective ethical treatment of postmenopausal osteoporosis

Today the American Association of Clinical Endocrinologists released new medical guidelines for the accurate diagnosis and effective ethical treatment of postmenopausal osteoporosis in affected patients.

11 Jan 2011

EffRx submits EX101 NDA for osteoporosis treatment to FDA

EffRx Pharmaceuticals SA, a Lausanne, Switzerland based drug delivery company announces the NDA submission of the company's lead project to the US Food and Drug Administration.

10 Jan 2011

Hologic announces acquisition of Interlace Medical

Hologic, Inc., a leading developer, manufacturer and supplier of premium diagnostics, medical imaging systems and surgical products dedicated to serving the healthcare needs of women, announced today it has acquired Interlace Medical, Inc. (Interlace), the developer and manufacturer of the MyoSure hysteroscopic tissue removal system (MyoSure). Interlace's operations will be integrated within Hologic's GYN Surgical Products division.

From Hologic, Inc. 7 Jan 2011

Ligand, Chiva Pharmaceuticals enter strategic relationship to develop multiple Ligand assets, technology

Ligand Pharmaceuticals Incorporated announced today that it has entered into a strategic relationship with Chiva Pharmaceuticals, to develop multiple Ligand assets and technology in China and potentially worldwide.

7 Jan 2011

Teva acquires Théramex

Teva Pharmaceutical Industries Ltd. announced today that it has completed the acquisition of Théramex, Merck KGaA's European-based women's health business.

5 Jan 2011

FDA approves Endo's FORTESTA Gel for low testosterone

Endo Pharmaceuticals today announced that the U.S. Food and Drug Administration (FDA) has approved FORTESTA Gel for the treatment of low testosterone, or 'Low T,' also known as hypogonadism. Symptoms associated with Low T include erectile dysfunction and decreased sexual desire, fatigue and loss of energy, mood depression, regression of secondary sexual characteristics and osteoporosis.

29 Dec 2010

International reference standards for use of bone turnover markers in clinical studies recommended

An expert working group of the International Osteoporosis Foundation (IOF) and the International Federation of Clinical Chemistry and Laboratory Medicine (IFCC) has released a new position paper which reviews the evidence of bone turnover markers (BTMs) in fracture risk prediction and monitoring of osteoporosis therapy. More importantly, it identifies research priorities and recommends that specific markers be used as reference analytes for BTMs in clinical and observational studies.

28 Dec 2010

Pfizer's sublicensing of Tanaproget triggers $1 million upfront payment to Ligand

Ligand Pharmaceuticals Incorporated announced today that its partner Pfizer, Inc. has granted a sublicense to a multi-national pharmaceutical company for Tanaproget, also known as NSP-989. As a result, Ligand will receive an upfront payment of $1 million from Pfizer. Ligand is entitled to clinical and regulatory milestone payments from Pfizer as Tanaproget advances through the development process, as well as tiered royalties on net sales.

23 Dec 2010

Kanis receives Hamdan Award for Medical Research Excellence in osteoporosis

Professor John A. Kanis is the winner of the 2010 Hamdan Award for Medical Research Excellence in the field of osteoporosis. The prestigious Award honours his outstanding contribution to the development and validation of a widely used fracture risk assessment tool

21 Dec 2010

Orthofix settles Trinity Evolution patent infringement suit with NuVasive and Osiris

Orthofix International N.V. today announced an internal reorganization designed to streamline operations within its three Global Business Units: Spine, Orthopedics and Sports Medicine. The Company expects to record a charge related to employee termination benefits of approximately $4.0 million ($2.4 million net of tax, or $0.13 per diluted share) in the fourth quarter of 2010 in connection with the reorganization.

16 Dec 2010

New research reports more than 10% of RA patients lack health literacy

Many patients seen at a rheumatology clinic—including some with a long history of rheumatoid arthritis (RA)—don't recognize important terms related to their health and medical treatment, reports a study in the December issue of JCR: Journal of Clinical Rheumatology.

15 Dec 2010

Unigene enters agreement with GSK to advance oral PTH Phase 2 program for osteoporosis

Unigene Laboratories, Inc. today announced that the Company entered into an amended and restated exclusive worldwide license agreement with GlaxoSmithKline (GSK) to develop and commercialize an oral formulation of a recombinantly produced parathyroid hormone (PTH) analog for the treatment of osteoporosis in postmenopausal women and plans to initiate a Phase 2 study in the first quarter of 2011.

14 Dec 2010

Osteoporosis News and Research

Latest Osteoporosis News and Research

Annual Society for Endocrinology BES conference to take place in UK from 11-14 April 2011

Research finds resistance training results in 20% decrease in person's blood pressure

Study: Pre-menopausal Chinese-American women have greater bone strength than Caucasian counterparts

USPSTF recommends women of ages 65 and above to routinely screen for osteoporosis

Unintended direct conflict between pharmaceutical marketing and public health

Patients' and doctors' perceptions of osteoporosis management differ

IOF welcomes EU Council Conclusions on chronic diseases, urges action in member states

TransPharma reports positive results from ViaDerm-Calcitonin Phase 1 trial for musculoskeletal disorders

New guidelines for accurate diagnosis, effective ethical treatment of postmenopausal osteoporosis

EffRx submits EX101 NDA for osteoporosis treatment to FDA

Hologic announces acquisition of Interlace Medical

Ligand, Chiva Pharmaceuticals enter strategic relationship to develop multiple Ligand assets, technology

Teva acquires Théramex

FDA approves Endo's FORTESTA Gel for low testosterone

International reference standards for use of bone turnover markers in clinical studies recommended

Pfizer's sublicensing of Tanaproget triggers $1 million upfront payment to Ligand

Kanis receives Hamdan Award for Medical Research Excellence in osteoporosis

Orthofix settles Trinity Evolution patent infringement suit with NuVasive and Osiris

New research reports more than 10% of RA patients lack health literacy

Unigene enters agreement with GSK to advance oral PTH Phase 2 program for osteoporosis

Small solutions for big problems in drug discovery and delivery

Professor Nancy Ip: Pioneering New Paths in Neurodegenerative Therapy

Utilizing process Raman in optimizing cultivated meat production

Osteoporosis News and Research

Latest Osteoporosis News and Research

Small solutions for big problems in drug discovery and delivery

Professor Nancy Ip: Pioneering New Paths in Neurodegenerative Therapy

Utilizing process Raman in optimizing cultivated meat production

Newsletters you may be interested in